Kolexia
Fornecker Luc-Matthieu Hématologie
Fornecker Luc-Matthieu
Hématologie
Hus Site Icans
Strasbourg, France
295 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Leucémies Leucémie chronique lymphocytaire à cellules B Lymphome à cellules du manteau Lymphome B diffus à grandes cellules Leucémie lymphoïde Lymphome T Lymphome B

Collaborateurs

Voir plus
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Feugier Pierre
Feugier Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Ysebaert Loic
Ysebaert Loic
Oncopole Toulouse, Toulouse, France
Ghesquieres Herve
Ghesquieres Herve
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Edimark
18 collaboration(s)
Dernière en 2023
Roche
15 collaboration(s)
Dernière en 2021
Janssen
13 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
11 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
Nature   11 décembre 2023
RESIST: REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy
Essai Clinique (BMS)   06 décembre 2023
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide Strategy for Innovative Clinical Trials
65th ASH Annual Meeting Abstracts   02 novembre 2023
Early Autologous Hematopoietic Stem Cells (AHSC) Boost (HCB) to Overcome Immune Effector Cell-Associated Hematotoxicity (ICAHT) after CAR T-Cell Therapy for Lymphoma: A Single Center Experience
65th ASH Annual Meeting Abstracts   02 novembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023